Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs

Frontiers in Public Health

Georgi Iskrov¹ 

关键词: health technology assessment;    reimbursement;    decision-making;    multi-criteria decision analysis;    orphan drugs;    rare diseases;   

DOI  :  10.3389/fpubh.2016.00214

学科分类：卫生学

来源: Frontiers

【 摘 要 】

BackgroundLimited resources and expanding expectations push all countries and types of health systems to adopt new approaches in priority setting and resources allocation. Despite best efforts, it is difficult to reconcile all competing interests, and trade-offs are inevitable. This is why multi-criteria decision analysis (MCDA) has played a major role in recent uptake of value-based reimbursement. MCDA framework enables exploration of stakeholders’ preferences, as well as explicit organization of broad range of criteria on which real-world decisions are made. Assessment and appraisal of orphan drugs tend to be one of the most complicated health technology assessment (HTA) tasks. Access to market approved orphan therapies remains an issue. Early constructive dialog among rare disease stakeholders and elaboration of orphan drug-tailored decision support tools could set the scene for ongoing accumulation of evidence, as well as for proper reimbursement decision-making.

【 授权许可】

CC BY